Prelude Therapeutics Incorporated
Stock Forecast, Prediction & Price Target

Prelude Therapeutics Incorporated Financial Estimates

Prelude Therapeutics Incorporated Revenue Estimates

Prelude Therapeutics Incorporated EBITDA Estimates

Prelude Therapeutics Incorporated Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$0
 
N/A
$0
 
0%
$0
 
0%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $8.3M
Low: $8.3M
High: $8.3M
avg. 0%
Avg: $21.7M
Low: $21.7M
High: $21.7M
avg. 161.44%
Avg: $37.88M
Low: $37.88M
High: $37.88M
avg. 74.56%
Net Income
 
% change YoY
$-110.77M
 
N/A
$-107.33M
 
3.10%
$-121.83M
 
-13.50%
Avg: $-138.38M
Low: $-85.10M
High: $-85.10M
avg. -13.58%
Avg: $-158.29M
Low: $-86.91M
High: $-86.91M
avg. -14.38%
Avg: $-82.08M
Low: $-82.08M
High: $-82.08M
avg. 48.14%
Avg: $-74.84M
Low: $-74.84M
High: $-74.84M
avg. 8.82%
EBITDA
 
% change YoY
$-113.73M
 
N/A
$-123.54M
 
-8.62%
$-131.10M
 
-6.12%
Avg: $0
Low: $0
High: $0
avg. 100%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
EPS
 
% change YoY
-$2.33
 
N/A
-$2.27
 
2.57%
-$2.02
 
11.01%
Avg: -$1.41
Low: -$1.41
High: -$1.41
avg. 30.19%
Avg: -$1.44
Low: -$1.44
High: -$1.44
avg. -2.12%
Avg: -$1.36
Low: -$1.36
High: -$1.36
avg. 5.55%
Avg: -$1.24
Low: -$1.24
High: -$1.24
avg. 8.82%
Operating Expenses
 
% change YoY
$113.73M
 
N/A
$123.54M
 
8.62%
$132.27M
 
7.07%
Avg: $0
Low: $0
High: $0
avg. -100%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%

FAQ

What is Prelude Therapeutics Incorporated stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 7.24% in 2025-2028.

We have gathered data from 1 analysts. Their low estimate is -85.10M, average is -138.38M and high is -85.10M.

What is Prelude Therapeutics Incorporated stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 59.00% in 2025-2028.

We have gathered data from 1 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.

What is Prelude Therapeutics Incorporated stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 10.61% in 2025-2028.

We have gathered data from 1 analysts. Their low earnings per share estimate is -$1.41, average is -$1.41 and high is $-1.41.

What is the best performing analyst?

In the last twelve months analysts have been covering Prelude Therapeutics Incorporated stock. The most successful analyst is Peter Lawson.